Urethral catheter with an ultrasound-triggered biopolymer drug-eluting coating containing methylprednisolone for the prevention of bladder neck contracture: clinical application
Abstract
Bladder neck contracture is considered one of the most common late complications of transurethral treatment of benign prostatic hyperplasia. Its incidence ranges from 0 to 10%–15%, reaching even higher values in the presence of risk factors, the most frequently discussed of which is a small volume of prostatic hyperplasia. The first stage of surgical treatment of benign prostatic hyperplasia involves transurethral incision or resection of the bladder neck; however, during long-term follow-up, the recurrence rate after this procedure may reach 50%–70%. In this context, various minimally invasive approaches to the management of bladder neck contracture have been proposed to improve treatment efficacy and safety. One such approach is balloon dilation of the bladder neck, which involves mechanical expansion of the fibrotic ring to stabilize the process at a urodynamically acceptable level. Balloon dilation may be combined with targeted pharmacological action of a drug directly on the affected tissue in parallel with mechanical expansion of the bladder neck. For this purpose, the balloon surface is coated with antiproliferative and antifibrotic agents. One such agent is the glucocorticoid methylprednisolone. In the present study, we report a clinical case of balloon dilation using a, ultrasound-triggered urethral catheter with a biopolymer drug-eluting coating (methylprednisolone) and provide illustrative visualization. Over a follow-up period of 31 months, the described patient…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.